Announces New Development Candidate - Glenmark Pharmaceuticals Ltd

Code BSE: 532296 NSE: $GLENMARK Ichnos Glenmark Innovation Announces New Development Candidate, ISB 2301, a First-inClass Multispecific Immune Cells Activator Targeting Solid Tumors Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing Multispecific™ antibodies in oncology, today announced a new development candidate, ISB 2301, a first-in-class, multispecific immune cells (T and NK) activator, for the potential treatment of multiple solid tumor indications. ISB 2301 targets three tumor-associated antigens to trigger tumor cell death and engages both T cells and NK cells to ignite the immune system.